Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Ga Jing Kee

Citation

Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426

Authors

G.J. Kee1, R. Tan2, R. Sultana3, M.W.W. Zaw4, W. Lian5, K.T.B. Tan6, R. Dent2, F.Y. Wong5, G.E. Lee7

Author affiliations

  • 1 Medicine, National University of Singapore, 117597 - Singapore/SG
  • 2 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 3 Duke-nus Medical School, Centre for Quantitative Medicine, Singapore/SG
  • 4 Department Of Anaesthesiology, Singapore General Hospital, Singapore/SG
  • 5 Division Of Radiation Oncology, National Cancer Centre Singapore, Singapore/SG
  • 6 Department Of General Surgery, Singapore General Hospital, Singapore/SG
  • 7 Division Of Medical Oncology, National Cancer Centre Singapore, Singapore/SG
More

Resources

Abstract 750

Background

Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows over-expression of human epidermal growth factor receptor 2 (HER2). This study aims to investigate the prevalence of HER2 positive (HER2+) ILC patients in Singapore and their clinical characteristics.

Methods

A retrospective review of female ILC patients seen between January 1985 and March 2018 at National Cancer Centre Singapore (NCCS) was conducted. Demographic and clinical data was collected from medical records. HER2+ ILC was defined as a score of 3+ on immunohistochemistry (IHC) or an IHC score of 2+ and a HER2/CEP17 ratio ≥2.0 for samples after 1 January 2014 and HER2/CEP17 ratio ≥2.2 for samples before 1 January 2014 on fluorescence in situ hybridization (FISH) testing. Clinical characteristics were evaluated in relation to HER2 status.

Results

A total of 1095 patients (mean age at diagnosis 55.3 years) were included; 784 Chinese (71.6%), 90 Malay (8.2%) and 77 Indian (7.0%). Distribution of ILCs by stage were: 282 Stage 1 (28.8%), 369 Stage 2 (37.7%), 247 Stage 3 (25.2%) and 67 Stage 4 (6.8%). Mean tumour size was 3.1cm (range 0 - 14.5cm), 112 of 858 patients with known tumour grade were grade 3 (13.1%) and 890 of 975 patients with known estrogen receptor (ER) status were ER + (91.3%). Prevalence of HER2+ ILC was 10.8% (100 of 929 patients with known HER2 status). HER2+ status was significantly associated with higher tumour grade (24 Grade 3 [24.0%], p < 0.001) and ER negativity (24 ER + [24.0%], p = <0.001) but not higher stage (29 Stage 3 [29.0%] and 9 Stage 4 (9.0%), p = 0.196).

Conclusions

Compared to reported HER2+ rates of 1-6% in previous ILC case series, 10.8% of patients in our large retrospective cohort were HER2+. HER2+ ILC were more likely to be ER negative and of higher tumour grade. Further studies are warranted to explore the biology and molecular characteristics of HER2+ ILC in Asian patients.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

National Cancer Centre Singapore.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings